Mark Stevenson

• Molecular genetics of syndromic and non-syndromic forms of parathyroid carcinoma.

  Cardoso L. et al, (2017), Hum Mutat

• Mice deleted for cell division cycle 73 gene develop parathyroid and uterine tumours: model for the hyperparathyroidism-jaw tumour syndrome.

  Walls GV. et al, (2017), Oncogene, 36, 4025 - 4036

• Epigenetic pathway inhibitors represent potential drugs for treating pancreatic and bronchial neuroendocrine tumors.

  Lines KE. et al, (2017), Oncogenesis, 6

• A MEN1 pancreatic neuroendocrine tumour mouse model under temporal control.

  Lines KE. et al, (2017), Endocr Connect, 6, 232 - 242

• Genomic profiling reveals mutational landscape in parathyroid carcinomas.

  Pandya C. et al, (2017), JCI Insight, 2

• Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1-Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression.

  Walls GV. et al, (2016), Endocrinology, 157, 1789 - 1798

• Animal models of pituitary neoplasia.

  Lines KE. et al, (2016), Mol Cell Endocrinol, 421, 68 - 81

• Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma: results from a large patient cohort.

  Dénes J. et al, (2015), J Clin Endocrinol Metab, 100, E531 - E541

• Whole-exome sequencing studies of parathyroid carcinomas reveal novel PRUNE2 mutations, distinctive mutational spectra related to APOBEC-catalyzed DNA mutagenesis and mutational enrichment in kinases associated with cell migration and invasion.

  Yu W. et al, (2015), J Clin Endocrinol Metab, 100, E360 - E364

• Inertial cavitation to non-invasively trigger and monitor intratumoral release of drug from intravenously delivered liposomes.

  Graham SM. et al, (2014), J Control Release, 178, 101 - 107

• Development of a Positive-readout Mouse Model of siRNA Pharmacodynamics.

  Stevenson M. et al, (2013), Mol Ther Nucleic Acids, 2

• E-selectin is a viable route of infection for polymer-coated adenovirus retargeting in TNF-α-activated human umbilical vein endothelial cells.

  Bachtarzi H. et al, (2011), J Drug Target, 19, 690 - 700

• Targeting adenovirus gene delivery to activated tumour-associated vasculature via endothelial selectins.

  Bachtarzi H. et al, (2011), J Control Release, 150, 196 - 203

• Development of a Transgenic Reporter Mouse for Positive-Readout siRNA Pharmacodynamic Analysis

  Stevenson M. et al, (2010), HUMAN GENE THERAPY, 21, 496 - 496

• Paclitaxel combined with siRNA targeting HPV16 oncogenes improves cytotoxicity for cervical carcinoma.

  Liu WL. et al, (2009), Cancer Gene Ther, 16, 764 - 775

• Quantitative characterization of cell transduction by HSV-1 amplicons using flow cytometry and real-time PCR.

  El-Sherbini YM. et al, (2009), J Virol Methods, 159, 160 - 166

• Establishment of a positive-readout reporter system for siRNAs.

  Liu WL. et al, (2009), J RNAi Gene Silencing, 5, 331 - 338

• Gene Delivery to Human Mesenchymal Stem Cells Using Helper Virus-Free Packaged HSV-1 Amplicons

  El-Sherbini YM. et al, (2009), MOLECULAR THERAPY, 17, S137 - S137

• Quantification of siRNA using competitive qPCR.

  Liu WL. et al, (2009), Nucleic Acids Res, 37

• Cancer gene therapy with targeted adenoviruses.

  Bachtarzi H. et al, (2008), Expert Opin Drug Deliv, 5, 1231 - 1240

• Delivery of siRNA mediated by histidine-containing reducible polycations.

  Stevenson M. et al, (2008), J Control Release, 130, 46 - 56

• Target peptide conjugate promoting efficient delivery of short interfering RNA (siRNA) into cervical cancer cells

  Liu WL. et al, (2008), HUMAN GENE THERAPY, 19, 403 - 403

• Retargeting adenovirus infection to endothelial cells in vitro via FLK-1 and E-selectin

  Bachtarzi H. et al, (2008), HUMAN GENE THERAPY, 19, 406 - 406

• Establishment of a positive-readout reporter system for siRNA

  Liu WL. et al, (2008), HUMAN GENE THERAPY, 19, 404 - 404

• Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer.

  Green NK. et al, (2008), J Gene Med, 10, 280 - 289

• Systemic delivery of 'Stealth' virus particles for the treatment of cancer

  Fisher KD. et al, (2007), JOURNAL OF GENE MEDICINE, 9, 528 - 528

• Incorporation of a laminin-derived peptide (SIKVAV) on polymer-modified adenovirus permits tumor-specific targeting via alpha6-integrins.

  Stevenson M. et al, (2007), Cancer Gene Ther, 14, 335 - 345

• Cytoplasmic expression systems triggered by mRNA yield increased gene expression in post-mitotic neurons.

  Farrow PJ. et al, (2006), Nucleic Acids Res, 34

• Chick embryo lethal orphan virus can be polymer-coated and retargeted to infect mammalian cells

  Stevenson M. et al, (2006), Gene Therapy, 13, 356 - 368

• Chick embryo lethal orphan virus can be polymer-coated and retargeted to infect mammalian cells.

  Stevenson M. et al, (2006), Gene Ther, 13, 356 - 368

• A versatile reducible polycation-based system for efficient delivery of a broad range of nucleic acids.

  Read ML. et al, (2005), Nucleic Acids Res, 33

• Oligopeptides as targeting structures in cancer theraPY.

  Pechar M. et al, (2005), J Control Release, 101, 376 - 379

• Stealth adenovirus entry to CNS neurons and glia

  Doyle K. et al, (2004), JOURNAL OF GENE MEDICINE, 6, S36 - S37

• Modifying adenovirus to improve safety and enable systemic administration

  Fisher KD. et al, (2004), JOURNAL OF GENE MEDICINE, 6, S3 - S4

• RNA-based therapeutic strategies for cancer

  Read ML. et al, (2003), Expert Opinion on Therapeutic Patents, 13, 627 - 638

• Adenovirus retargeting and systemic delivery.

  Seymour LW. et al, (2003), Ernst Schering Res Found Workshop, 107 - 114

Recent Publications

• Molecular genetics of syndromic and non-syndromic forms of parathyroid carcinoma.

  Cardoso L. et al, (2017), Hum Mutat

• Mice deleted for cell division cycle 73 gene develop parathyroid and uterine tumours: model for the hyperparathyroidism-jaw tumour syndrome.

  Walls GV. et al, (2017), Oncogene, 36, 4025 - 4036

• Epigenetic pathway inhibitors represent potential drugs for treating pancreatic and bronchial neuroendocrine tumors.

  Lines KE. et al, (2017), Oncogenesis, 6

• A MEN1 pancreatic neuroendocrine tumour mouse model under temporal control.

  Lines KE. et al, (2017), Endocr Connect, 6, 232 - 242

• Genomic profiling reveals mutational landscape in parathyroid carcinomas.

  Pandya C. et al, (2017), JCI Insight, 2